SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 9, 2005
-----------------
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 000-23143 13-3379479
- ---------------------------- ----------- -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
777 Old Saw Mill River Road, Tarrytown, New York 10591
---------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (914) 789-2800
--------------
--------------------------------------------------------------
(Former name or former address, if changed since last report.)
Section 7.01 - Regulation FD Disclosure
On September 9, 2005, the Company announced positive phase 1 clinical
findings regarding its investigational drug, PRO 140, a novel HIV entry
inhibitor. PRO 140 is a humanized monoclonal antibody against CCR5 that is
designed to protect healthy immune system cells from infection by the human
immunodeficiency virus (HIV), the causative agent of AIDS. Dose-dependent
binding of PRO 140 to CCR5-expressing cells was reported in the clinical trial,
with the highest PRO 140 concentration tested significantly coating CCR5 cells
for at least 60 days. The CCR5 co-receptor is a key portal of entry used by HIV
to infect immune system cells; therefore, blocking this molecular doorway
represents an important therapeutic target. A copy of the press release is
attached hereto as Exhibit 99.1 and the information contained therein is
incorporated by reference into this Item 7.01 of this Current Report on Form
8-K.
The information furnished pursuant to Item 7.01 in this Form 8-K shall not be
deemed to be "filed" for the purposes of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that Section, unless we
specifically incorporate it by reference in a document filed under the
Securities Act of 1933 or the Securities Exchange Act of 1934. We undertake no
duty or obligation to publicly update or revise the information furnished
pursuant to Item 7.01 in this Form 8-K.
Section 9.01 - Financial Statements and Exhibits
(c) Exhibits
Exhibit Number Description
99.1 Press release dated September 9, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PROGENICS PHARMACEUTICALS, INC.
By: /s/ MARK R. BAKER
---------------------------------------------
Mark R. Baker
Senior Vice President & General Counsel
Date: September 9, 2005